Global Bronchitis Treatment Market Size study, by Class of Drugs (Antibiotics, Anti-inflammatory Drugs, Bronchodilator, Other), by End-User (Hospital Pharmacies, Retail Pharmacies, Other), by Type (Acute Bronchitis, Chronic Bronchitis) and Regional Foreca

Global Bronchitis Treatment Market Size study, by Class of Drugs (Antibiotics, Anti-inflammatory Drugs, Bronchodilator, Other), by End-User (Hospital Pharmacies, Retail Pharmacies, Other), by Type (Acute Bronchitis, Chronic Bronchitis) and Regional Forecasts 2022-2028

Global Bronchitis Treatment Market is valued at approximately USD 5921.89 million in 2021 and is anticipated to grow with a healthy growth rate of more than 6.64 % over the forecast period 2022-2028. Bronchitis is an inflammation of the bronchial tube lining that is accompanied by coughing up thicker, discoloured mucus. Bronchitis is a respiratory disorder in which the bronchi in the lungs become inflamed. Bronchitis, to put it another way, is an inflammation of the bronchial tubes that convey air to and from the lungs. Cough, weariness, shortness of breath, chest tightness, mucus production, and other symptoms of bronchitis are all prevalent. The increasing prevalence of smoking and increase in respiratory disorders has led to the adoption of Bronchitis Treatment across the forecast period. For Instance: as per the National Library of Medicine in 2022, each year, approximately 5% of adults get acute bronchitis. Approximately 90% of these seek medical counsel for the same reason. Acute bronchitis is one of the top 10 most prevalent illnesses among outpatients in the United States. As per the Institute for Health Metrics and Evaluation in 2021, Smoking's massive worldwide health toll is highlighted by the most complete data on global trends in smoking. In 2019, the number of smokers worldwide climbed to 1.1 billion, with tobacco smoking accounting for 7.7 million deaths globally, including one in every five male fatalities. According to Healthy People in 2020, asthma affects more than 25 million people in the United States. COPD has been diagnosed in around 14.8 million adults, with another 12 million persons waiting to be diagnosed. Also, the increase in Chronic obstructive pulmonary disease (COPD) and increase in product approvals are likely to increase the market growth during the forecast period. However, drug release is subject to strict regulations, and approval costs are high which can obstruct the Market's expansion over the projection period of 2022-2028.

The key regions considered for the Global Bronchitis Treatment market study include Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world in terms of market share owing to the increasing prevalence of smoking coupled with the increase in respiratory disorders. Whereas, Asia-Pacific is also anticipated to exhibit the highest growth rate over the forecast period 2022-2028. Factors such as a growing tendency of young people to smoke, as well as an increasing number of strategic activities by market players would create lucrative growth prospects for the Bronchitis Treatment market across Asia-Pacific region.

Major market players included in this report are:
AstraZeneca plc
Novartis AG
GlaxoSmithKline plc
Dr. Reddy's Laboratories Ltd.
Sanofi S.A
Boehringer Ingelheim International GmbH
Pfizer Inc.
Melinta Therapeutics
Lupin Limited
Cadila Healthcare Limited
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Class of Drugs:
Antibiotics
Anti-inflammatory Drugs
Bronchodilator
Other
By End-User:
Hospital Pharmacies
Retail Pharmacies
Other)
By Type:
Acute Bronchitis
Chronic Bronchitis
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Bronchitis Treatment Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

AstraZeneca plc
Novartis AG
GlaxoSmithKline plc
Dr. Reddy's Laboratories Ltd.
Sanofi S.A
Boehringer Ingelheim International GmbH
Pfizer Inc.
Melinta Therapeutics
Lupin Limited
Cadila Healthcare Limited

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.